CalciMedica, Inc. CALC
Set alert
At close · Oct 30
After hours · Oct 30, 7:36 PM ET
- YTD
- -95.57%
- 1 year
- -90.23%
- Open
- 1.79
- Prev close
- 1.75
- Mkt cap
- 9.97M
- Vol
- 112.19K
- Avg vol
- 82.50K
- EPS
- -6.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.61
- High
- 1.84
- Forward P/E
- -1.69
- Beta
- 0.00
- Short ratio
- 1.68
- Inst. own
- 43.87%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 3.46
- 200-d avg
- 4.33
- 1y target
- 17.00
News
1 day ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor…
1 week ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
-
2 weeks ago benzinga.com
CalciMedica Announces Stephen Bardin To Resign As CFO Effective After Q3 2026 10-Q Filing
On October 15, 2026, Stephen Bardin, the Chief Financial Officer, principal accounting officer and principal financial officer of CalciMedica, Inc. (the "Company"), provided notice of his…
-
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock rose 34.9% to $2.94 during Thursday's after-market session. The market value of their outstanding shares is at $7.6 million. Senti Biosciences…
2 weeks ago defenseworld.net
CalciMedica Inc. (NASDAQ:CALC) Stock Has Average Price Target of $50.00 According to Analysts
Shares of CalciMedica Inc. (NASDAQ: CALC - Get Free Report) have been assigned a consensus rating of "Hold" from the five brokerages that are covering the stock, MarketBeat reports. One analyst has…
-
1 month ago benzinga.com
CalciMedica Files Prospectus Supplement For Up To $25M At-The-Market Common Stock Offering
https://www.sec.gov/Archives/edgar/data/1534133/000119312526409041/d145394d424b5.htm
1 month ago globenewswire.com
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium…
-
2 months ago benzinga.com
CalciMedica Announces 1-For-5 Reverse Stock Split, Effective August 28
CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for
2 months ago globenewswire.com
CalciMedica Announces One-for-Five Reverse Stock Split
LA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium…
-
2 months ago benzinga.com
Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9
Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.
-
2 months ago benzinga.com
CalciMedica Q2 EPS $(0.45) Misses $(0.28) Estimate
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.28) by 60.71 percent. This is a 12.5 percent decrease over losses of…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
-
3 months ago benzinga.com
Following Type C FDA Meeting, Calcimedica Has Aligned On Phase 2b Trial Endpoints And Patient Population Enrichment Strategy For Its Planned Registration Program Evaluating Auxora In Acute Pancreatitis
CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibition therapies for…
3 months ago prnewswire.com
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
FDA aligned on new-onset severe respiratory failure as the Phase 2b primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary endpoints FDA aligned on a…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 million. CalciMedica (NASDAQ:CALC)…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi…
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 67.3% to $2.08 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. The company's, Q1 earnings…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's regular session. The market value of their outstanding shares is at $22.1 million. Icecure Medical…
4 months ago benzinga.com
FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances Trial
FDA raises no objections to CalciMedica revised Phase 2 KOURAGE trial, allowing Auxora dosing to resume for acute kidney injury.
-
4 months ago benzinga.com
Market-Moving News for June 24th
FDX: -7% | FedEx shares are trading lower. The company reported Q4 financial results. LFS: 42% | LEIFRAS shares are trading higher after the company announced it will acquire SWIFT JAPAN. CALC: 60% |…
-
4 months ago benzinga.com
CalciMedica Announces Private Placement Worth Up To ~$49M In Gross Proceeds
The financing includes participation from new and existing investors, including members of CalciMedica's Board of Directors and management team. In the private placement, the Company will sell an…
-
4 months ago benzinga.com
CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With Auxora
CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for
4 months ago prnewswire.com
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral…
4 months ago prnewswire.com
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients No comments or questions were received Confirms CalciMedica's ability to continue…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
5 months ago benzinga.com
CalciMedica Q1 EPS $0.30 Beats $(0.28) Estimate
CalciMedica (NASDAQ:CALC) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $(0.28) by 207.14 percent. This is a 183.33 percent increase over losses of…
5 months ago prnewswire.com
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
8 months ago prnewswire.com
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ D esign of…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
9 months ago benzinga.com
This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
9 months ago benzinga.com
CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis
CalciMedica, Inc. (NASDAQ: CALC) shares are down on Wednesday after the company announced the discontinuation of its Phase 2 KOURAGE clinical trial.
9 months ago benzinga.com
Nasdaq Gains 150 Points; Starbucks Shares Rise After Strong Sales
Nasdaq Gains 150 Points; Starbucks Shares Rise After Strong Sales
9 months ago prnewswire.com
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026…
10 months ago zacks.com
Airbus Clinches Contract to Supply 30 A320neo Aircraft to CALC
EADSY lands a firm order for 30 A320neo aircraft from CALC, reinforcing strong global demand for its fuel-efficient single-aisle aircraft.
10 months ago defenseworld.net
CalciMedica (NASDAQ:CALC) Trading Down 2.1% – Time to Sell?
CalciMedica Inc. (NASDAQ: CALC - Get Free Report) traded down 2.1% during trading on Tuesday. The company traded as low as $5.55 and last traded at $5.73. 44,801 shares were traded during mid-day…
11 months ago prnewswire.com
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA on pivotal trial in acute…
11 months ago prnewswire.com
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination with…
11 months ago prnewswire.com
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
Treatment with Auxora significantly reduced IL-17–related inflammation in both kidney and lung, significantly increased glomerular filtration rate (GFR), and decreased renal injury in a rat model of…
1 year ago prnewswire.com
CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™
AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials LA JOLLA, Calif. , Oct. 14, 2025 /PRNewswire/…
1 year ago prnewswire.com
CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
LA JOLLA, Calif. , Sept. 2, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium…
1 year ago prnewswire.com
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 Productive initial meeting with the FDA on Auxora in acute…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
1 year ago prnewswire.com
CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
LA JOLLA, Calif. , July 8, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium…